Aktis Oncology 3Q 2026: Revenue $3.91M, EPS ($0.54) — 10-Q Summary
Aktis Oncology reported 3Q 2026 revenue of $3.91M, up 147% YoY, but net loss widened to $29.94M due to increased R&D and employee costs. Clinical programs AKY-2519 and AKY-1189 saw higher spending, while collaboration revenue from Eli Lilly was $3.9M. Cash reserves totaled $492.9M, expected to fund operations into 2029.
How this was made
The 30-second read
Why it matters
The earnings release introduces new financial data that could shift market perception of AKTS, especially given the widened loss versus revenue growth.
Market read
Primary relevance to AKTS shareholders; secondary relevance to biotech sector participants.
What to watch
Collaboration revenue from Eli Lilly ($3.9M) and a strong cash position ($492.9M) provide runway to 2029, which may mitigate concerns over the current loss.
Background
Aktis Oncology filed its Q3 2026 Form 10‑Q, detailing financials, clinical program spending, and cash resources.
Ticker impact
Q3 2026 10-Q shows revenue up 147% YoY but net loss widened to $29.94M, EPS -$0.54, indicating higher R&D spend and employee costs.
likely downward pressure as investors price in widened loss despite revenue growth
The report is the first public disclosure of the quarterly results; the loss expansion is material for a micro‑cap biotech.
Market effects
Biotech sector may see modest pullback as a peer reports higher losses despite revenue growth.
Limited to US biotech investors; no broader regional effect.
Low global relevance; primarily affects AKTS shareholders and niche biotech funds.
Counterpoint
Revenue surge could signal future upside if R&D pipeline advances, making the stock a potential long‑term play despite short‑term loss.
Key entities
- companyAktis Oncology, Inc.
US‑listed biotech reporting Q3 2026 results.
- partnerEli Lilly
Collaboration partner providing $3.9M revenue.